Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study

臺大醫學院-腫瘤醫學研究所;Melero, I.I.MeleroSangro, B.B.SangroYau, T.T.YauHsu, C.C.HsuKudo, M.M.KudoCrocenzi, T.T.CrocenziKim, T-Y.T-Y.KimChoo, S-P.S-P.ChooTrojan, J.J.TrojanMeyer, T.T.MeyerWelling, T. H., IIIT. H., IIIWellingYeo, W.W.YeoChopra, A.A.ChopraAnderson, J.J.AndersonDela Cruz, C.C.Dela CruzLang, L.L.LangNeely, J.J.NeelyEl-Khoueiry, A.A.El-Khoueiry2017-06-272018-07-092017-06-272018-07-092016http://ntur.lib.ntu.edu.tw//handle/246246/280178Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study10.1093/annonc/mdw371.0710.1093/annonc/mdw371.7